All Activity

The most exceptional personal pleasure comes from the impressive Escorts in Alaknanda and their alluring services. Rest assured about your safety and confidentiality.

“Rescheduling removes a major structural penalty, but tariffs will reshape who captures the gains. All else equal, dispensary-heavy companies may emerge as the primary beneficiaries.” By Justin Leiby, Cannabis Research Institute With federal cannabis rescheduling partially underway and the potential end of the 280E tax penalty approaching, how much relief the cannabis industry will experience is an open question. No matter what the future holds, 280E is a significant financial drag on cannabis operators. I run an annual survey of cannabis operators for the Illinois Cannabis Regulation Oversight Office, and in the most recent survey operators estimate that 44 percent of their 2024 operating expenses were nondeductible under 280E, which only applies to Schedule I and Schedule II drugs. Assuming a 21 percent corporate tax rate, this translates into a $92 penalty for every $1,000 spent. Beyond the (hopefully) temporary importance of distinguishing medical versus adult-use operations under the Trump administration’s current process of moving cannabis to Schedule III, the pain of the 280E penalty has not been evenly distributed—and those who suffered the most may reap greater benefits. Smaller operators report more 280E disallowances than larger companies (45 percent vs. 37 percent of operating expenses), as do companies that rely entirely on dispensary operations versus those that don’t (50 percent vs. 43 percent). Comparing The Impacts Of 280E And Tariffs To put the financial impact of rescheduling in context, one should consider that some of the benefits may never hit operators’ bottom lines thanks to the impact of tariffs imposed over the past year. I combine survey responses from Illinois with public financial filings to better understand the relative impacts. Like all businesses, cannabis operators have two types of operating costs: the direct costs of acquiring and producing their products like raw materials (“costs of goods sold”) and the indirect costs of operating the business like rent and insurance (“selling, general, and administrative expenses” or “SG&A”). Tariffs primarily impact the former, larger chunk, while 280E primarily impacts the latter. Together, these costs consume 84 cents of every dollar of revenue that cannabis operators generate, while paying creditors and non-280E taxes consumes another six cents. I estimate a 280E penalty of three cents per dollar by multiplying a 44 percent average disallowance, the 35 percent SG&A percentage, and the 21 percent U.S. corporate tax rate. Given the small profit margins in cannabis, the financial benefit of eliminating the 280E penalty is undeniable. However, this will be partially or completely offset by tariffs increasing input costs like packaging, vape hardware and construction materials. One in six operators reports input cost increases of 20 percent or more and over half report increases of 5 percent or more. In my example, even a modest 5 percent increase erases most of the benefit from 280E penalty relief and an 18 percent increase erases all profits altogether. Variable and Delayed Benefits Much like 280E, the tariff burden falls heavier on some operators than others—in this case, on cultivation and infusion operations that rely on imported packaging products, buildouts and high-tech hardware. One in six cultivation and infusion companies (17 percent) report input cost spikes exceeding 20 percent, while no dispensary-only company reported this impact. Because dispensary-only operators face larger tax distortions from 280E and report smaller impacts from tariffs, they may benefit the most from ending the 280E penalty. Rescheduling Changes The Competitive Landscape Rescheduling removes a major structural penalty, but tariffs will reshape who captures the gains. All else equal, dispensary-heavy companies may emerge as the primary beneficiaries. That said, observations like this should start the discussion rather than settle it. Some benefits of rescheduling won’t materialize immediately, because operators have made long-term strategic choices based on 280E tax constraints and cannot unwind these choices instantly. For instance, in the Illinois survey over half of operators report that 280E led them to cut discretionary investments in product development, research and sustainable technologies required for a market to mature. Similar percentages report moving to leaner staffing models, which can impact everything from safety protocols to customer experience, and modifying facility layouts due to tax considerations, e.g., limiting retail sales space that is harder to deduct. “Who wins” depends on how well operators can adapt to the new landscape. Justin Leiby, PhD, is a professor of accountancy in the Gies College of Business at the University of Illinois and a faculty in residence at the Cannabis Research Institute. His research and teaching focuses on auditing, governance and risk management, and includes extensive collection and analysis of operational and financial data in the cannabis industry. The post Tariffs’ Impact On Some Cannabis Businesses May Erase Any Benefits They See From 280E Tax Relief Under Rescheduling (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Drug Enforcement Administration (DEA) is being put on notice—again—over prolonged delays in processing a petition to reschedule psilocybin from a doctor who wants to use it to treat terminally ill patients, with an updated reminder that President Donald Trump has now made clear his administration’s intent to streamline psychedelic medicine access. In a letter sent to an appellate staffer with the Justice Department’s civil division on Wednesday, an attorney representing Sunil Aggarwal of the AIMS Institute laid out the years-long timeline since a petition was first filed with DEA in 2022 requesting that psilocybin be moved from Schedule I to Schedule II of the Controlled Substances Act (CSA). Aggarwal and AIMS have been working since at least 2020 to find a way to legally obtain psilocybin for patients in palliative care, initially seeking to win permission from regulators under state and federal right-to-try (RTT) laws. However, after a dizzying back-and-forth that involved an initial DEA denial of the rescheduling petition, appeals, court hearings and DOJ’s forwarding of the rescheduling petition to the Department of Health and Human Services (HHS) in August 2025, the agency went silent. “We have had no information about the status of the petition since that time, despite a series of inquiries,” attorney Shane Pennington of the law firm Blank Rome LLP wrote in the letter to Daniel Aguilar of the U.S. Department of Justice’s Civil Division on Wednesday. He added that the Food and Drug Administration (FDA) under HHS has already extensively reviewed relevant scientific data into psilocybin that should, in theory, expedite a resolution in Aggarwal’s petition case. The FDA review ultimately resulted in the agency twice granting breakthrough therapy status to the investigational psychedelic drug, so “it is clear that thorough and careful scrutiny has already occurred,” Pennington said. That makes DOJ’s explanation about the continued petition review delays all the more “perplexing.” “FDA necessarily examined the vast majority of the relevant evidence, data, and scientific literature before it granted multiple Breakthrough designations to psilocybin,” he said. “Any additional data and evidence since that time is consistent with all the prior data and evidence and has been in hands of HHS and FDA since the transmittal from DEA in August of 2025.” What has changed since that time, however, is the fact that the president signed an executive order last month “directing that rescheduling of psychedelic substances be streamlined,” while recognizing that psychedelic substances such as psilocybin “show potential in clinical studies to address serious mental illnesses for patients.” The letter continues to quote from Trump’s order: “Indeed, the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to specific psychedelic drugs, and there are numerous products currently in the clinical trial pipeline for review of safety and efficacy. It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America.” “The EO explicitly addresses ‘timely rescheduling,’ and while that section of the EO refers to substances which have completed Phase 3 clinical trials, the intent of the President is clear: investigational drugs with proven value in clinical trials, and which have been granted Breakthrough status, ought be fast tracked for agency action to begin to open access to those in need,” Pennington said. The attorney also noted that FDA “recently granted national priority review vouchers to two companies studying psilocybin to accelerate their path through the drug-approval process,” and so it stands to reason that the agency’s “commitment to its view of the science and data on psilocybin has only strengthened since DEA referred the petition to HHS in August of last year.” “In light of these developments, it is unclear what further analysis could possibly be necessary to make a recommendation on Dr. Aggarwal’s rescheduling petition,” the letter concludes. “Please review this history, and urge your client to promptly move forward.” To Pennington’s point about the administration’s position on psychedelics, HHS Sec. Robert F. Kennedy, Jr. said at last month’s executive order signing event that under the president’s order, his department “will accelerate research, approval and access to new mental health treatments, including psychedelic therapies.” “We’re taking this decision, this decisive step, to confront one of the most urgent public health challenges facing our nation, the mental health crisis,” he said. “This executive order will remove legal impediments that block American researchers, scientists, physicians and clinicians from properly studying these medicines and, where appropriate, establishing protocols for their safe therapeutic use.” Kennedy also said recently that the Trump administration is “very anxious” to create a pathway for access to psychedelics therapy and that top officials across federal agencies want to “get it out to the public as quickly as possible.” Read the attorney’s psilocybin rescheduling letter to DOJ below: The post DEA Should ‘Promptly Move Forward’ With Psilocybin Rescheduling In Light Of Trump’s Psychedelics Order, Attorney For Doctor Behind Petition Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I can see that you are an expert at your field! I am launching a website soon, and your information will be very useful for me.. Thanks for all your help and wishing you all the success in your business. slot gacor

Thanks for sharing this information. I really like your blog post very much. You have really shared a informative and interesting blog post with people.. koitoto

Virginia’s governor is seeking to explain why she vetoed legislation to legalize recreational marijuana sales in the state this week—saying she supports the overall reform but took issue with some of the details in the proposal that lawmakers sent her, including what she called a “rushed timeline” to launch the legal cannabis market and “far more stores across Virginia” than she thinks are appropriate. “I continue to support the creation of a retail marijuana market,” Gov. Abigail Spanberger (D) said in an interview with WRIC-TV on Wednesday, pointing to current state law that allows adults to possess and grow cannabis for personal use but provides them no place to legally purchase it. “That’s an obvious bridge that we need to gap, but we need to do it with thoughtful, focused, implementable legislation.” Lawmakers passed the cannabis sales bills in March, but the governor then suggested changes to the legalization proposal—including delaying the start date for sales by six months, increasing taxes and instituting new criminal penalties for cannabis consumers. The legislature last month declined to take up the amendments during a one-day reconvened session, however, effectively rejecting them. Spanberger then issued a veto on Tuesday. In the new interview, the governor said her proposed amendments were “extraordinarily important for our ability to implement cannabis retail market, to do it in a thoughtful, measured way that learns from the mistakes of other states.” Spanberger has repeatedly responded to criticism of her cannabis amendments from the bill sponsors and advocates by saying the suggested changes came after she spoke to the leaders of other states that have already implemented adult-use marijuana markets. A spokesperson for Spanberger was not able to provide a list of other governors she talked to about cannabis in response to a question from Marijuana Moment this week, however. In any case, Spanberger told WRIC that she wants to use other states’ experiences “to make sure that we are setting the market up to be a durable one” in Virginia. “The notion that between July and January we would be able to build out all of the rules of the road for legal recreational marijuana market and have doors open to sales in January is a rushed timeframe and one that would not necessarily allow us to learn from the mistakes of other states who have spoken to the fact that a rushed timeline is challenged,” she argued. The governor also expressed concerns that under the now-vetoed legislation’s provisions, the state would be “moving in place aggressively with far more stores across Virginia, without the ability for potential retailers to be able to grow in some level of expertise and make sure that the market is meeting the actual demand.” Here is Governor Spanberger's (@GovernorVA) full answer on her veto of bills to create a retail market for recreational marijuana sales. 1. She says she still supports the creation of a retail marijuana market. 2. Spanberger says starting retail sales on January 1 created a… pic.twitter.com/EhGLpjR1Ag — Tyler Englander (@TylerEnglander) May 20, 2026 Spanberger said lawmakers “chose not to entertain any of my amendments,” though it is the case that she sent them back an entire substitute rewrite of the legislation instead of proposing specific discrete changes they could consider individually. “That is absolutely their prerogative, but it is also my prerogative as the chief executive of the Commonwealth of Virginia, and the one who will be tasked with setting up a successful or a unsuccessful marijuana market to ensure that we are getting it right. And it was their prerogative to reject and not even take under consideration any of my amendments, and so that puts us back in a place where we get to continue the conversation.” “It’s important we have a retail marijuana market, because again, the gray area is not one that is long-term tenable, but we have to get it right,” she said. “I look forward to partnering with members of the General Assembly to do that, and I hope that they recognize that most important to me is to make sure that we get it right—set it up to be durable and successful, ensure the rules of the road are clear, that individuals who might be purchasing know what they are purchasing and what they are consuming, that it takes into consideration public health, and particularly the safety and health of our kids.” “Those are my core priorities, and those will continue to be my core priorities as we are working on a bill that will pass and that I will ultimately and eventually sign,” Spanberger said. Prior to vetoing the cannabis commerce bill, the governor did sign separate legislation to provide resentencing relief for people with past cannabis convictions. Personal marijuana possession and home cultivation of marijuana has been legal in Virginia since 2021, but then-Gov. Glenn Youngkin (R) twice vetoed bills to provide consumers with a way to legally purchase regulated adult-use cannabis. Sen. Lashrecse Aird (D), and Del. Paul Krizek (D), the sponsors of the legalization bills, had urged colleagues to vote against the governor’s amendments last month—even if that meant risking a veto from Spanberger when the legislation returned to her desk, which has now occurred. Lawmakers will now have to start the push for reform over again with new bills in the 2027 session. Here are the other key details of the cannabis bills—SB 542 and HB 642—as approved by lawmakers and with the governor’s suggested amendments: Lawmakers voted to allow adults to be able to purchase up to 2.5 ounces of marijuana in a single transaction, or up to an equivalent amount of other cannabis products as determined by regulators. That would represent an increase from the limit in current law of 1 ounce. The governor, however, wanted the amount increased to only 2 ounces. Under the legislature’s plan, legal sales could begin on January 1, 2027, but the governor proposed to push that back to July 1, 2027. Lawmakers voted to impose an excise tax of 6 percent on cannabis sales as well as a 5.3 percent retail sales and use tax, while allowing municipalities to set an additional local tax of up to 3.5 percent. The governor’s plan was largely the same, though it would have increased the excise tax to 8 percent starting on July 1, 2029. Under the legislation as approved by lawmakers, revenue would have been distributed to the Cannabis Equity Reinvestment Fund (30 percent), early childhood education (40 percent), the Department of Behavioral & Developmental Health Services (25 percent) and public health initiatives (5 percent). The governor, however, wanted to put all revenue into the general fund while earmarking it “for purposes such as early childhood education, behavioral health, public health awareness, prevention, treatment, and recovery services, workforce development, reentry, indigent criminal defense, and targeted reinvestment in historically disadvantaged communities.” The Virginia Cannabis Control Authority would have overseen licensing and regulation of the new industry, and would have also taken on oversight of hemp, which is currently under the Department of Agriculture and Consumer Services. Local governments could not have opted out of allowing marijuana businesses to operate in their area. Delivery services would have been allowed. Serving sizes would have been capped at 10 milligrams THC, with no more than 100 mg THC per package. The governor proposed to make public marijuana use a class 4 criminal misdemeanor instead of civil violation punishable by a $25 fine as under current law. She also wanted to make possessing cannabis by people under the age of 21 a class 1 misdemeanor, punishable with a mandatory minimum fine of $500 or 50 hours of community service, as well as the suspension of drivers licenses for at least six months. Illegally selling or distributing 50 pounds or more of marijuana would have been a class 2 felony punishable by life in prison. The governor sought to eliminate support for the Cannabis Equity Reinvestment Fund. Existing medical cannabis operators could have entered the adult-use market if they pay a licensing conversion fee that was set at $10 million. Cannabis businesses would have had to establish labor peace agreements with workers. As passed by lawmakers, the bill would have directed a legislative commission to study adding on-site consumption licenses and microbusiness cannabis event permits that would allow licensees to conduct sales at venues like farmers markets or pop-up locations, but the governor proposed to remove that language. A coalition of cannabis reform organizations sent the governor a letter this month urging her not to veto the sales legalization legislation even though her amendments were rejected. “Together, these bills address the real issues surrounding cannabis in the Commonwealth today: an already-existing, unregulated marijuana market operating openly across the state while consumers, communities, and law enforcement are left without the protections of a legal framework,” the groups wrote. “Let’s be clear: these bills do not create a marijuana market in Virginia. That market already exists,” the letter said. “What these bills do is replace today’s predatory and unaccountable illicit operators with a regulated marketplace, enforceable rules, oversight, product safeguards, age verification, and the strict consumer safety standards already in use for Virginia medical cannabis.” The letter was signed by Virginia NORML, Marijuana Justice, Virginia Cannabis Association, Marijuana Policy Project and other groups. Separately, a coalition of hemp businesses that joined with a major alcohol retailer in asking Spanberger to veto the marijuana bill before she did so said the move presents an “opportunity” to craft better cannabis policy. Meanwhile, the governor signed several other reform bills last month—including measures to protect the parental rights of marijuana consumers and allow patients to access medical cannabis in hospitals. The post Virginia Governor Explains Marijuana Veto, Saying She Worried About ‘Rushed Timeline’ And Too Many Dispensaries appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Great write-up, I am a big believer in commenting on blogs to inform the blog writers know that they’ve added something worthwhile to the world wide web!.. 강남가라오케

Our Escorts in Dwarka companions are available for "silent dates." We have clients who simply want to exist in the same space as a beautiful woman without talking. She'll read a book while you work, nap together, or watch TV in companionable silence. Introverts, this is for you.

I went over this website and I believe you have a lot of wonderful information, saved to my bookmarks 강남가라오케

Genuine bonds are built through trust and desire. Their Call Girls Service in Global Radiance Hotel provides intimate companions who treat every fantasy as sacred. They build physical pleasure patiently, then release it as earth-shattering orgasm. Their trustworthy partners are discreet, devoted, and wildly passionate. Whether a quiet evening or a night of adventure, perfection is guaranteed. Let them transform your hotel stay into a memory you will replay forever.

A Republican running to become Pennsylvania’s lieutenant governor says that legalizing marijuana would be “catastrophic” for the state, claiming it would increase the size of the illegal market, undermine job creation and harm public health. Jason Richey, who won the primary this week for the GOP lieutenant governor nomination, criticized Democrats for seeking to raise needed revenue for the state through cannabis legalization. “These budgets that are 7 billion over how much we bring in, and then the answer is, ‘we’re going to legalize drugs,’ which is going to be catastrophic,” he said on WILK radio’s Bob Cordaro Show. “We know from Colorado, for instance, that the black market quadruples the amount of supply into a state when marijuana gets legalized,” Richey claimed. “Employers don’t want to come to the state because they don’t want a workforce on drugs. DUI, or impaired driving up, mental health up, ER visits up. I mean, who wants that?” The GOP candidate said that scenario is the “vision” of incumbent Gov. Josh Shapiro (D), who supports legalizing cannabis. “The Dems are this close to realizing it. And that’s why Stacy and I have stepped up,” he said, referring to Republican gubernatorial nominee Stacy Garrity. “We are going to fight back, and we’re going to take full control,” Richey said in the interview on Monday, one day ahead of the state’s primary election in which he and Garrity won the nomination of their party for the offices they are seeking. “And I think if we do and put conservative economic principles into play, we have a chance to help millions and millions of Pennsylvanians.” Richey’s comments align with the position of his running mate, Garrity, who currently serves as state treasurer. Late last month, Garrity pledged to veto a marijuana legalization bill if lawmakers ever sent one to her desk—though she added that she doesn’t think the reform stands a chance of making it that far in the state. “I don’t support legalizing recreational marijuana,” she said. “Recreational marijuana will not end up in the budget. They’re never going to pass it…not as long as Senate Republicans are in control of the Senate.” Richey’s claims about cannabis legalization’s effect on the illegal market in Colorado run in contrast to what that state’s governor says the impact of the policy has been. “Colorado has collected over $3B in marijuana tax revenue to pave roads, build schools, rec centers and so much more, all while successfully cracking down on the underground market,” Gov. Jared Polis (D) said last year in response to similar criticism of marijuana reform from Florida Gov. Ron DeSantis (R). The Pennsylvania GOP ticket’s opposition to legalizing cannabis is in stark contrast to the stance of incumbent Shapiro, who has repeatedly called on lawmakers to send him a marijuana legalization bill and for the last several years has included the reform in his budget requests to the legislature. The Democratic-controlled House of Representatives passed a bill last year to end prohibition, but the Republican-controlled Senate has not followed suit. Before her recent veto pledge, Garrity had previously largely dodged questions about whether she supports legalizing cannabis—saying last year, for example that she has no “policy position” on the issue while arguing that the Shapiro’s proposal for reform “way, way overstated” potential revenue. But in 2020, when Garrity was running for treasurer, she filled out a Pennsylvania Family Council survey that asked about a number of policy positions, including cannabis legalization. “Should marijuana be legalized for recreational use?” it asked. According to an archived version of her responses, Garrity’s response to the cannabis question was “N.” Campaign staff for the Republican candidate did not respond to a request for comment from Marijuana Moment about whether the Trump administration’s move to federally reschedule the drug last month makes her more likely to back reform at the state level. Shapiro’s campaign, however, told Marijuana Moment that their candidate “has been clear that as nearly every one of our neighboring states has already legalized marijuana, we cannot afford to keep losing out on this revenue—and we need comprehensive cannabis reform to make Pennsylvania more competitive and more just.” “While Stacy Garrity wants Pennsylvania to continue to lose out on critical revenue that could be invested into our schools, public safety and small businesses, Governor Shapiro is continuing to fight to get this done,” Shapiro for Pennsylvania Spokesperson Sam Reposa said. A spokesperson in the governor’s office separately said last month that the Trump administration’s federal marijuana rescheduling move is an “important step” that “adds support” to his push to legalize cannabis in the state. The governor also used last month’s unofficial cannabis holiday 4/20 as an opportunity to press lawmakers once again to send him a bill to legalize marijuana. “Pennsylvanians who want to buy recreational marijuana are already driving across the border to one of our neighboring states who’ve legalized it,” Shapiro said in a social media post that day. “That’s hundreds of millions in revenue going out of state instead of being spent here in Pennsylvania.” Last month, the Pennsylvania House of Representatives passed budget legislation proposed by Shapiro that relies on revenue that would be generated from recreational marijuana sales, which has yet to be legalized in the state. The governor earlier this year, as he has in past years, included cannabis legalization and the resulting expected revenue in his budget request. The $53.2 billion budget legislation, which doesn’t itself include provisions to actually legalize marijuana even as it contemplates allocating money that would result from it, now heads to the Senate for consideration. The House of Representatives last year passed a bill to legalize marijuana and put sales in state-owned dispensaries, but the Republican Senate majority has criticized that plan while also not advancing a cannabis legalization model of its own. Separately last month, the House Health Committee approved a bill to allow terminally ill patients to use medical cannabis in hospitals and other healthcare facilities The legislative developments come as a recent poll shows that seven out of ten Pennsylvania likely voters support legalizing adult-use marijuana—including majority backing for the reform across party lines. When asked whether they “support or oppose the regulation and taxation of legal cannabis for use by adults 21 and older in Pennsylvania,” 69 percent of respondents said yes. Support was strongest from Democrats, at 72 percent, but also includes 67 percent of Republicans and 64 percent of independents. Meanwhile, Shapiro is continuing to pressure on lawmakers to send him a bill to legalize marijuana in the state, saying that doing so would generate new revenue that could be invested in key programs. “While some in Harrisburg claim we can’t afford to make bigger investments in our kids, public safety, and our economy, know this: If we legalized and regulated adult-use cannabis, we’d bring in $1.3 BILLION in revenue for our Commonwealth over the first five years,” the governor said in another recent social media post. “Those are dollars that can be invested back into our people and our communities,” he said. “Stop with the excuses. Let’s get this done.” The state’s Independent Fiscal Office (IFO) reported in February that legalizing cannabis in Pennsylvania would generate nearly half a billion dollars in annual revenue by 2028, an estimate that is a significantly larger cash windfall compared to projections from Shapiro’s own office. With a proposed 20 percent wholesale cannabis excise tax, 6 percent state sales tax for retail and licensing fees, IFO said the governor’s legalization plan would generate $140 million in tax revenue in the first year of implementation from 2027-2028 and increase to $432 million by 2030-2031. That’s a much higher revenue estimate than what the governor’s office put forward in the latest executive budget. According to his office’s analysis, legalization would generate about $36.9 million in tax dollars in its first year from a 20 percent wholesale tax on marijuana—rising gradually to $223.8 million by 2030-2031. In February, a coalition of drug policy and civil liberties organizations urged Shapiro to play a leadership role in convening legislative leaders to get the job done on cannabis legalization this session. The Senate Law and Justice Committee this month amended and approved a bill to create a Cannabis Control Board (CCB) to oversee the state’s medical marijuana program and intoxicating hemp products and that could eventually regulate adult-use cannabis if it is legalized in the state. The post Pennsylvania GOP Lieutenant Governor Candidate Says Marijuana Legalization Would Be ‘Catastrophic’ For The State appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

What a fantabulous post this has been. Never seen this kind of useful post. I am grateful to you and expect more number of posts like these. Thank you very much. toto slot

You make so many great points here that I read your article a couple of times. Your views are in accordance with my own for the most part. This is great content for your readers. 강남가라오케

Excellent publish, Thanks with regard to discussing This particular understanding. Wonderfully created post, if perhaps just about all writers provided exactly the same degree of content material while you, the web will be a far better location. Make sure you continue the good work! link togel

Poll: Marijuana cooler than crypto; VA hemp biz say veto an “opportunity”; LA medical marijuana in hospitals vote; Study: CBG for rheumatoid arthritis Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… BREAKING: Journalism is often consumed for free, but costs money to produce! While this newsletter is proudly sent without cost to you, our ability to send it each day depends on the financial support of readers who can afford to give it. So if you’ve got a few dollars to spare each month and believe in the work we do, please consider joining us on Patreon today. https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The Transportation Security Administration clarified to Marijuana Moment that its policy on bringing medical cannabis into airports and on planes “has not changed” despite clickbait headlines to the contrary. “Periodic website updates occur for clarity and conciseness. TSA’s policy remains the same. No changes have been made.” A new poll of U.S. adults shows that they think marijuana is less cool than math or country music—but is cooler than guns, sports betting and cryptocurrency. In a separate question, respondents overrated how cool other people think cannabis is as compared to their own views. Louisiana lawmakers sent Gov. Jeff Landry (R) a bill to allow patients with terminal and irreversible conditions to use medical cannabis in hospitals, subject to certain limitations. The Cannabis Small Business Association, which together with alcohol retailer Total Wine & More had asked Virginia Gov. Abigail Spanberger (D) to veto a recreational marijuana sales legalization bill over concerns about its hemp provisions, said her decision to do so is an “opportunity” to craft better cannabis policy in 2027. A new study found that the cannabis component CBG “has anti-inflammatory capacity and therapeutic potential in regulating neutrophil-mediated immunity in” rheumatoid arthritis. Cannabigerol “exerts a regulatory effect by limiting inflammatory immune cell recruitment to inflamed joints.” Workers at a BeLeaf Medical subsidiary in St. Louis, Missouri won a union vote when the National Labor Relations Board rejected the company’s argument that ballots from more than two years ago should remain sealed. / FEDERAL The Department of Defense inspector general is conducting an evaluation of military strikes on suspected drug boats. Customs and Border Protection included a warning in a Memorial Day travel advisory that “while legal in some municipalities, marijuana remains illegal under U.S. federal law.” Kansas Democratic U.S. House candidate Chris Carmichael said federal marijuana legalization would create jobs and generate tax revenue. The House bill to allow Department of Veterans Affairs doctors to issue medical cannabis recommendations got one new cosponsor for a total of four. The House bill to protect veterans from losing their benefits over marijuana use got one new cosponsor for a total of two. / STATES Maryland Gov. Wes Moore (D) cited his mass marijuana pardon in response to a question about whether he’s progressive. A Virginia senator said Gov. Abigail Spanberger (D) is a “false hope” after she vetoed recreational marijuana sales legalization legislation. Arizona regulators announced a recall of marijuana products that may be contaminated with aspergillus. A Massachusetts Department of Public Health spokesperson said losing marijuana revenue if a ballot initiative to roll back the state’s legalization law passes could harm the Bureau of Substance Addiction Services or other service areas. A University of Colorado regent who was censured for criticizing a public health campaign about cannabis is suing her colleague over the dispute. The New Jersey Business Action Center published an annual report on the Cannabis Training Academy. Missouri regulators are hosting forums and webinars for prospective marijuana microbusiness license applicants. Oregon regulators hear an overview of marijuana licensing operations on Thursday. / INTERNATIONAL Sint Maarten’s minister of tourism, economic affairs, transport and telecommunication defended the government’s progress in implementing cannabis legalization. / SCIENCE & HEALTH A study found that cannabis “vapes emitted significantly less toxic emissions per puff than the joint in almost all categories, usually by an order of magnitude or more.” / ADVOCACY, OPINION & ANALYSIS A poll of Utah voters showed that they support legalizing marijuana, 52 percent to 43 percent. / BUSINESS Innovative Industrial Properties, Inc. closed on four secured term loans totaling $44.9 million in gross proceeds. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post TSA clarifies “no changes” in medical cannabis policy for airports (Newsletter: May 21, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Numerous news organizations over the past week have run exaggerated headlines about a supposed change in the federal government’s policy on bringing marijuana into airports and on airplanes. But it isn’t true, the Transportation Security Administration (TSA) tells Marijuana Moment. “TSA’s policy on medical marijuana has not changed,” a TSA spokesperson said in an email on Wednesday. “Per TSA’s website: If any illegal substance or evidence of criminal activity is discovered during security screening, TSA will refer the matter to a law enforcement officer,” they said. While it is true that the agency’s listing for medical marijuana on the “What Can I Bring?” section of its website was updated on April 27, there was no substantive change in the policy. The site currently says that “Yes,” travelers can bring medical marijuana in both carry on and checked bags, with special instructions. But TSA cannabis policy has said “Yes” to medical marijuana, with the same caveats, since 2019. Both the current version of the page that was updated last month and an archived version from seven years ago say the following: “TSA’s screening procedures are focused on security and are designed to detect potential threats to aviation and passengers. Accordingly, TSA security officers do not search for illegal drugs, but if any illegal substance or evidence of criminal activity is discovered during security screening, TSA will refer the matter to a law enforcement officer.” The previous version also had this language about federally legal hemp products, but it has now been removed in the latest update: “Possession of marijuana and certain cannabis infused products, including some Cannabidiol (CBD) oil, remain illegal under federal law. TSA officers are required to report any suspected violations of law, including possession of marijuana and certain cannabis infused products. Products/medications that contain hemp-derived CBD or are approved by the FDA are legal as long as it is produced within the regulations defined by the law under the Agriculture Improvement Act 2018.” Many news organizations that didn’t bother to compare the current version of the TSA page with the prior one seem to have assumed that the Trump administration’s move to federally reschedule cannabis last month had caused the air travel safety agency to make a change in its policy, but that is not the case. “Periodic website updates occur for clarity and conciseness,” the TSA email to Marijuana Moment on Wednesday said. “TSA’s policy remains the same. No changes have been made.” Other agencies, meanwhile, have made cannabis policy changes in line with federal rescheduling. The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) has posted a draft update to a gun purchase form to acknowledge the federally legal status of medical marijuana under rescheduling. The revised section in question notably says that only “use or possession of marijuana for recreational purposes” is federally prohibited, leaving out the prior form’s mention of medical cannabis. The U.S. Department of the Treasury and Internal Revenue Service (IRS) said they plan to issue new tax guidance for the marijuana industry following rescheduling. The reform will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions they’re currently barred from under an IRS code known as 280E that doesn’t apply to Schedule III substances. Even the Drug Enforcement Administration (DEA), which has long opposed cannabis legalization and was accused of stalling the rescheduling process initiative by the Biden administration, has launched a registration process for state-legal marijuana businesses to take advantage of federal benefits that come with the reform. The Department of Transportation, however, clarified last week that truck drivers, airline pilots and other federally regulated safety-sensitive workers still cannot use medical marijuana without being punished. TSA, for its part, posted a marijuana-pun-filled rant to commemorate National Brownie Day back in 2020. “We hear it’s National Brownie Day so we’re here to toke about something really sticky-icky-icky (ooh wee),” the federal agency posted to its Instagram account. “Hopefully this doesn’t post near 4:20, because we’re about to doobie down.” Following that high-flying introduction was a public service announcement of sorts, warning travelers not to bring cannabis through airports. “Marijuana whether dank or schwag, it isn’t dope in your carry-on or checked bag,” the post says, establishing a rhyme scheme and then immediately disregarding it: “This includes cannabis products and CBD oil, which remain illegal under federal law, except for products that contain no more than 0.3% THC on a dry weight basis or that are @FDA approved.” Among the hashtags included in the post are “#NationalBrownieDay,” “USAtraveling,” “#leaveitathome,” “#chronnic” (misspelled) and “#maryj.” Image element courtesy of Steve Fitzgerald. The post TSA Clarifies That Its Marijuana Policy ‘Has Not Changed’ Despite Clickbait Headlines appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Louisiana lawmakers have passed a bill to let patients with terminal and irreversible conditions use medical marijuana in hospitals, sending it to the governor. The House of Representatives approved the legislation from Sen. Katrina Jackson-Andrews (D) in a 54-44 vote on Tuesday after it previously passed the Senate by a margin of 33-2 last month. It now heads to the desk of Gov. Jeff Landry (R). Under the proposal, hospitals would have to create written guidelines allowing covered patients to consume medical cannabis on-site in forms other than smoking or vaping. Under an amendment adopted by a Senate committee last month, emergency or outpatient departments would be exempted from the policy. The revised legislation also clarifies that patients and primary caregivers are responsible for acquiring and administering medical marijuana, which must be “stored securely at all times in a locked container provided by the patient.” Health care professionals and staff would be prohibited from “administering, storing, retrieving, or assisting the patient with the medical marijuana,” the text says. The amendment, which the sponsor worked on with help from the Louisiana Hospital Association, also allows hospitals to opt out of the policy if federal officials take action against any healthcare facility in the state over medical cannabis use, rather than only allowing those that were specifically targeted to stop complying. “This bill was brought at the request of constituents who believe that therapeutic medical marijuana, which is already legal in this state, should be offered in hospitals when patients are terminally ill or otherwise in need the comfort of this medicine,” Jackson-Andrews told the Senate Health and Welfare Committee when the panel took up the legislation. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile in Louisiana, another piece of drug policy legislation that has traction this session would create a psychedelic-assisted therapy pilot program, using opioid settlement dollars to fund clinical trials aimed at developing alternative treatments such as psilocybin, and ibogaine. Separately, a lawmaker recently filed a proposal that would create a new state task force to “study and develop findings and recommendations regarding the potential legalization of recreational marijuana.” At the same time, however, advocates are alarmed that lawmakers sent the governor legislation that threatens to send people to jail for up to one year if they smoke marijuana within 2,000 feet of a school property—including a college campus. Another Louisiana legislator, meanwhile, recently introduced a bill to create an adult-use marijuana legalization pilot program in the state to determine whether the reform should eventually be expanded and permanently codified. Rep. Candace Newell (D)—who has long championed legislation to end cannabis criminalization and filed a similar legal marijuana pilot program measure last session—is sponsoring what’s titled the “Adult-Use Cannabis Pilot Program Regulation and Enforcement Act.” Getting the bill across the finish line could prove complicated in the conservative legislature, however. Newell’s earlier version of the pilot program legislation didn’t advance to enactment last year, and lawmakers that session also rejected other marijuana reform proposals such as one that would have established a tax system to prepare the eventual legalization of adult-use cannabis. The post Louisiana Bill To Let Terminally Ill Patients Use Medical Marijuana In Hospitals Heads To Governor Following Legislature’s Approval appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“People in this field definitely need somebody to stick up for them, because it’s a little easy to get steamrolled.” By Rebecca Rivas, Missouri Independent It’s been about two years since Will Braddum was fired from his position at Sinse marijuana cultivation and manufacturing facility in south St. Louis, Missouri, along with more than a dozen others. For him, the marijuana industry had been a career, but he’d seen how “cutthroat” the corporate side can be, he said, and how vulnerable he and other employees were without representation. “The only way to pad myself from human resources is to cultivate a union movement and talk to my co-workers about job security,” Braddum said in an interview with The Independent in 2023. It’s been more than two years since Braddum and other Sinse employees voted in an election to unionize. The majority of the ballots had remained sealed because BeLeaf Medical, the facility’s parent company, challenged them—a challenge the company recently lost. On Friday, the ballots were finally opened, revealing a long-awaited 11-3 vote in favor of unionization. “It’s kind of like bittersweet,” Braddum said soon after the ballots were revealed Friday. “It’s really nice to have changed the industry for the better, even if the people over at Sinse don’t decide to go in the direction of unionizing and protecting their own rights, at least they have the opportunity now. It sets a precedent.” BeLeaf Medical’s owners have been arguing since 2023 that their “post-harvest workers” don’t have the right to unionize because they’re agricultural workers. Earlier this month, the National Labor Relations Board, which is the highest administrative body on labor conflicts and sets national policy on unionizing, rejected the company’s argument that employees are agricultural workers. Agricultural workers are excluded from the National Labor Relations Act, the federal law that protects most private-sector employees’ right to unionize without fear of retaliation. “We agree with the regional [NLRB] director, for the reasons provided in her decision, that none of the workers employed in the classifications at issue here are agricultural laborers under the secondary definition of agriculture,” the national board members wrote. The Sinse employees whose union votes BeLeaf questioned largely made pre-rolls, entered data on computers and processed dried marijuana into finished products, the board found. Douglas Purvis, BeLeaf Medical’s director of human resources, told the Independent in an emailed statement that the company respects “the outcome and the wishes of our employees.” “BeLeaf Medical is committed to bargaining in good faith,” Purvis said, “and look forward to working together toward a mutually acceptable agreement.” Several Sinse workers who organized the union effort and voted in the election gathered at a brewery in St. Louis to celebrate Friday evening. “Obviously, I wish the ballots would have been opened a little sooner,” said Scotti Iman, who worked at Sinse for more than two years. “I think this kind of shows that people in this field definitely need somebody to stick up for them, because it’s a little easy to get steamrolled.” Iman was among the original organizers, but he left his position to take care of a family member before the election. Iman said several workers made “sacrifices” to get it done and that Sean Shannon, a lead organizer with UFCW Local 655 who has been working with the Sinse employees since fall 2023, “worked his butt off to get this over the finish line.” “The votes are out and in the open now,” Iman said. “That’s awesome.” Shannon said the next step is to send a request to start setting bargaining dates, which the union plans to do Monday. Laura Kelley, president of UFCW Local 655, said the BeLeaf election shows why unions were first put in place. “The most important thing we have is our voice,” Kelley said, “and our attorney did a great job of making sure that their voices were heard. Labor has been around a long time, and I think sometimes people forget what we actually stand for—and we stand for that voice.” This story was first published by Missouri Independent. The post Missouri Marijuana Workers Win Union Vote After Federal Officials Reject Company’s Argument On Blocking Ballots appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A coalition of hemp businesses that asked Virginia’s governor to veto legislation to legalize recreational marijuana sales before she did so this week says the move presents an “opportunity” to craft better cannabis policy. The Cannabis Small Business Association said in a press release on Tuesday that while its members support the idea of creating a “well-regulated adult-use cannabis market,” they were concerned that the now-vetoed bills would have “left Virginia’s existing small hemp operators and family-owned cannabis businesses without a viable path forward.” “The veto is not a conclusion,” CSBA’s release said. “It is an opportunity.” Days before Gov. Abigail Spanberger (D) vetoed the cannabis commercialization legislation, CSBA, hemp companies and major alcohol retailer Total Wine & More sent the governor a letter asking her to do so and then “revisit” the issue in the 2027 session after “thorough stakeholder engagement and economic policy expert input.” The main thrust of the legislation was to create a framework for legal and regulated sales of adult-use marijuana, but provisions inserted at the last minute before the proposal was sent to the governor’s desk last month would have also made significant changes to Virginia’s rules for hemp. In particular, the final bill would have made it so only hemp products with no more than 2 milligrams of total THC per package would be legal. The letter from CSBA and its allies also raised concerns about the timelines in the marijuana legislation for the launch of the legal market as well as what it called the “expedited enforcement” of hemp restrictions, which it said together offer “limited realistic plant-touching opportunities for small and independent businesses” and “could prove to be devastating to aspiring and existing, law-abiding operators.” “Across the commonwealth, farmers, manufacturers and retailers have invested significant time and resources in reliance on changing laws over the past,” the groups wrote. “These enterprises support local economies, create jobs and provide consumers with access to lawful, regulated products. As the policy environment evolves, good-faith operators must not be displaced without a clear and practical path forward.” “Rather than prohibiting existing regulated product categories or excluding current participants, we encourage solutions that establish a safe adult-use market while maintaining continuity for compliant businesses. This means creating realistic, accessible pathways—by preserving the existing regulated hemp market, establishing transition mechanisms into the adult-use framework, and allowing both to coexist in a complementary and safe manner. A market structure that gives advantages to large, well-capitalized corporate operators over Virginia’s existing small businesses would undermine the very communities this legislation is meant to serve.” Barbara Biddle, who serves as president of CSBA and is also the founder of District Hemp Botanicals, stressed in a press release following Spanberger’s veto that the group “fully supports adult-use cannabis legalization in Virginia.” “What we could not support was this particular legislation and the consequences it would have had for small businesses and existing lawful operators who built this industry from the ground up,” she said. “We are grateful that Governor Spanberger took those concerns seriously. This veto is not a setback for legalization. It is a reset—and an invitation to do this right, together.” JM Pedini, development director for the advocacy group NORML and executive director for Virginia NORML, pushed back against the notion that the veto was ultimately good for cannabis policymaking. “Thousands of Virginians sent emails in support of these bills, but in the end their voices were outweighed by a handful of corporations led by a major alcohol retailer with a financial stake in preserving Virginia’s unregulated intoxicating THC market,” Pedini told Marijuana Moment on Wednesday. Looking ahead to 2027, CSBA said for its part that it will push for a cannabis regulatory framework that: Establishes clear, accessible licensing pathways for Virginia’s existing small hemp operators and independent cannabis businesses Provides workable transition timelines that allow compliant businesses to adapt without facing sudden financial collapse Builds a market structure that reflects Virginia’s entrepreneurial community—not one that consolidates early advantage among large, out-of-state operators Prioritizes consumer safety and market integrity alongside small business inclusion, treating these goals as complementary rather than competing Engages a broad coalition of stakeholders—farmers, manufacturers, retailers, consumers, and community members—throughout the drafting process Meanwhile, however, the federal recriminalization of hemp THC products looms. Hemp derivatives with less than 0.3 percent delta-9 THC on a dry-weight basis were federally legalized under the 2018 Farm Bill that President Donald Trump signed during his first term in office. But late last year, Trump signed new legislation containing provisions that will redefine hemp to make it so only products with 0.4 milligrams of total THC per container will remain legal after November 12. Several members of Congress have filed legislation to delay or alter the scheduled ban, but so far those proposals have not gained traction with leadership in the House of Representatives or Senate. Back in Virginia, lawmakers passed the cannabis sales bills in March, but the governor then suggested changes to the legalization proposal—including delaying the start date for sales by six months, increasing taxes and instituting new criminal penalties for cannabis consumers. The legislature last month declined to take up the amendments during a one-day reconvened session, however, effectively rejecting them. Personal marijuana possession and home cultivation of marijuana has been legal in Virginia since 2021, but then-Gov. Glenn Youngkin (R) twice vetoed bills to provide consumers with a way to legally purchase regulated adult-use cannabis. Last week, Spanberger signed separate legislation to provide resentencing relief for people with past cannabis convictions. Sen. Lashrecse Aird (D) and Del. Paul Krizek (D), who sponsored the recreational cannabis sales legalization bills, criticized the governor’s veto on Tuesday, as did marijuana reform groups. Aird and Krizek had urged colleagues to vote against the governor’s amendments last month—even if that meant risking a veto from Spanberger when the legislation returned to her desk, which has now occurred. Spanberger, for her part, responded to earlier criticism of her cannabis amendments from the bill sponsors and advocates by saying the suggested changes came after she spoke to the leaders of other states that have already implemented adult-use marijuana markets. Here are the other key details of the cannabis bills—SB 542 and HB 642—as approved by lawmakers and with the governor’s suggested amendments: Lawmakers voted to allow adults to be able to purchase up to 2.5 ounces of marijuana in a single transaction, or up to an equivalent amount of other cannabis products as determined by regulators. That would represent an increase from the limit in current law of 1 ounce. The governor, however, wanted the amount increased to only 2 ounces. Under the legislature’s plan, legal sales could begin on January 1, 2027, but the governor proposed to push that back to July 1, 2027. Lawmakers voted to impose an excise tax of 6 percent on cannabis sales as well as a 5.3 percent retail sales and use tax, while allowing municipalities to set an additional local tax of up to 3.5 percent. The governor’s plan was largely the same, though it would have increased the excise tax to 8 percent starting on July 1, 2029. Under the legislation as approved by lawmakers, revenue would have been distributed to the Cannabis Equity Reinvestment Fund (30 percent), early childhood education (40 percent), the Department of Behavioral & Developmental Health Services (25 percent) and public health initiatives (5 percent). The governor, however, wanted to put all revenue into the general fund while earmarking it “for purposes such as early childhood education, behavioral health, public health awareness, prevention, treatment, and recovery services, workforce development, reentry, indigent criminal defense, and targeted reinvestment in historically disadvantaged communities.” The Virginia Cannabis Control Authority would have overseen licensing and regulation of the new industry, and would have also taken on oversight of hemp, which is currently under the Department of Agriculture and Consumer Services. Local governments could not have opted out of allowing marijuana businesses to operate in their area. Delivery services would have been allowed. Serving sizes would have been capped at 10 milligrams THC, with no more than 100 mg THC per package. The governor proposed to make public marijuana use a class 4 criminal misdemeanor instead of civil violation punishable by a $25 fine as under current law. She also wanted to make possessing cannabis by people under the age of 21 a class 1 misdemeanor, punishable with a mandatory minimum fine of $500 or 50 hours of community service, as well as the suspension of drivers licenses for at least six months. Illegally selling or distributing 50 pounds or more of marijuana would have been a class 2 felony punishable by life in prison. The governor sought to eliminate support for the Cannabis Equity Reinvestment Fund. Existing medical cannabis operators could have entered the adult-use market if they pay a licensing conversion fee that is set at $10 million. Cannabis businesses would have had to establish labor peace agreements with workers. As passed by lawmakers, the bill would have directed a legislative commission to study adding on-site consumption licenses and microbusiness cannabis event permits that would allow licensees to conduct sales at venues like farmers markets or pop-up locations, but the governor is proposing to remove that language. A coalition of cannabis reform organizations sent the governor a letter this month urging her not to veto the sales legalization legislation even though her amendments were rejected. “Together, these bills address the real issues surrounding cannabis in the Commonwealth today: an already-existing, unregulated marijuana market operating openly across the state while consumers, communities, and law enforcement are left without the protections of a legal framework,” the groups wrote. “Let’s be clear: these bills do not create a marijuana market in Virginia. That market already exists,” the letter said. “What these bills do is replace today’s predatory and unaccountable illicit operators with a regulated marketplace, enforceable rules, oversight, product safeguards, age verification, and the strict consumer safety standards already in use for Virginia medical cannabis.” The letter was signed by Virginia NORML, Marijuana Justice, Virginia Cannabis Association, Marijuana Policy Project and other groups. Meanwhile, the governor signed several other reform bills last month—including measures to protect the parental rights of marijuana consumers and allow patients to access medical cannabis in hospitals. Read the full letter asking the governor to veto the marijuana sales bill below: The post Virginia Hemp Groups Say Governor’s Marijuana Sales Veto Is An ‘Opportunity’ appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I really thank you for the valuable info on this great subject and look forward to more great posts Loyang Valley Enbloc

I read that Post and got it fine and informative. https://slot-web.com/

A lesser known cannabis component known as CBG could represent a novel treatment in the treatment of rheumatoid arthritis (RA), according to a new study. Researchers at the Rambam Health Care Campus in Israel released preclinical findings from a study examining cannabigerol, a non-intoxicating cannabinoid, and its potential to reduce inflammation associated with arthritis. While most conventional RA therapies target certain proteins called cytokines, the study authors described using CBG to directly regulate white blood cells, or neutrophils, that can release certain cytokines linked to inflammation. The research findings were recently published in the journal Pharmaceuticals. The preclinical study involved introducing CBG to isolated neutrophils extracted human blood cells, as well as administering the cannabis compound to lab mice. Researchers determined that “CBG has anti-inflammatory capacity and therapeutic potential in regulating neutrophil-mediated immunity in RA.” “To date, there is no treatment that specifically targets neutrophils,” the study authors wrote. Yet they found that “CBG reduces the inflammatory output of human neutrophils by suppressing TNF-α and IL-6 production,” referring to select cytokines. “These findings highlight CBG as an effective preclinical modulator candidate for affecting neutrophil-mediated immune responses and attenuating inflammation in rheumatoid arthritis.” Specifically, cannabigerol was associated with deceases in the cytokines IL-6 by 98 percent and IL-1β by 60 percent. It also reduced MCP-1 by 22 percent and IL-1β by 38 percent in the joints. For the analysis of the isolated human cells, researchers found that CBG made it less likely that neutrophils would target an inflammatory signal, which is important because immune cells moving toward joints are a key part of the cycle associated with arthritis-related damage. In the mice portion of the study, test subjects treated with the cannabinoid showed improved arthritic scores and were less likely to experience weight loss compared to the untreated group. The disease still manifested, but with less severity. “These findings demonstrate that CBG exerts a regulatory effect by limiting inflammatory immune cell recruitment to inflamed joints in RA-diseased mice,” they said, while adding that human RA “is a highly heterogeneous and chronic condition” and “further long-term clinical studies are necessary” to confirm the efficacy of the cannabinoid in RA therapy. It should be noted that the company Raphael Pharmaceutical Inc., which supplied the CBG used in the study, provided partial funding for the research. The findings build on prior research, including a 2024 study that found, among people with rheumatic conditions such as arthritis, more than 6 in 10 patients who used medical cannabis reported substituting it for other medications, including NSAIDs, opioids, sleep aids and muscle relaxants. Most patients further said that the use of marijuana allowed them to reduce or stop using those medications entirely. In 2018, meanwhile, a study published in the journal Frontiers indicated that another non-intoxicating cannabinoid, CBD, can alleviate the symptoms of osteoarthritis in dogs. The post The Cannabis Component CBG Shows Promise In Treating Rheumatoid Arthritis With Its ‘Anti-Inflammatory Capacity,’ Study Finds appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

This article brings up an important discussion about alternative treatments for postpartum depression. It's great to see more conversations about cannabis as a potential solution, as mentioned in the Good Housekeeping piece about motherhood and mental health. For more insights, check out this related article on scritchy scratchy.

This article brings up an important discussion about alternative treatments for postpartum depression. It's great to see more conversations about cannabis as a potential solution, as mentioned in the Good Housekeeping piece about motherhood and mental health. For more insights, check out this related article on scritchy scratchy.

I definitely enjoying every little bit of it. It is a great website and nice share. I want to thank you. Good job! You guys do a great blog, and have some great contents. Keep up the good work. slot online